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Supramolecular hydrophobic guest transport
system based on pillar[5]arene†
Zhenhui Qi, Katharina Achazi, Rainer Haag, Shengyi Dong* and
Christoph A. Schalley*
A pillar[5]arene-based bioactive guest loading system has been
developed, which can increase the solubility of the drug norharmane
in aqueous medium, and also enable its pH-stimulated release.
Furthermore, this supramolecular transport system reduces the
toxicity of loaded guest.
The development of eﬃcient and responsive guest-loading com-
plexes is not only of fundamental scientific interest, but also
exerts significant value for pharmaceutical applications.1 Supra-
molecular structures involving macrocycles have been an intense
area of research, because they serve as models for understanding
natural supramolecular self-assemblies and molecular recogni-
tion motifs, and more importantly, they provide precursors for
designing novel nanomaterials for biomedical applications.2
Currently, there is an urgent need for methods that improve
the solubility of poorly soluble bioactive candidates, because
an estimated 40–70% of new chemical entities belong to
Biopharmaceutics Classification System (BCS) Class II, which
comprises compounds with low solubility, but high intestinal
permeability.3 Supramolecular entities, such as host–guest
complexes,4 supramolecular polymers,5 vesicles and micelles,6
have gained increased attention in applications as guest trans-
port systems. These entities not only trap high-energy forms of
bioactive ingredients owing to their high binding constant
(Ka 4 10
4 M1), but also expose dynamical, stimuli-responsive,
and controllable guest-recognition behaviour, which enables the
release of molecules under external stimuli.
Pillar[n]arenes (P[n]s) are a new class of macrocyclic hosts beside
crown ethers,7 cyclodextrins,8 calixarenes,9 and cucurbiturils.10 The
repeating units of P[n]s are connected by methylene bridges in
the two para-positions, forming rigid pillar-like architectures.11
The unique structures and easy functionalization of pillararenes
have given them outstanding abilities to selectively bind diﬀerent
kinds of guests and provided a useful platform for the construc-
tion of many interesting supramolecular systems, including cyclic
dimers,12 chemosensors,13 supramolecular polymers,14 and trans-
membrane channels.15 However, exploring P[n]s’ applications in
biomedical fields, particularly as a drug loading system, is still in
its infancy.16 The main reason can be ascribed to the limited
information available on the biocompability of P[n]s. Also, little
eﬀort has been devoted to gaining insight on their host–guest
complexation behaviour with bioactive molecules.17 Just recently,
for example, Huang’s group reported a pillararene-based ternary
drug-delivery system with photo-controlled anticancer drug
release.17a Wang et al. described P[6]-derived vesicles that can
entrap model drugs and realize controlled release.17b,c In these
P[n]s-based loading systems, the main design strategy was to
introduce suitable guest molecules to construct supramolecular
amphiphiles along with P[n]s via host–guest chemistry, which
could then further assemble into micelles/vesicles. The model
drugs were loaded during the preparation of these assemblies
and then exposed to dialysis. Apparently, this type of formula-
tion strategy inevitably required several synthetic steps for host/
guest molecules as well as additional purification processes.
Moreover, the preparation of large-scale amounts was probably
going to be even more costly. To realize loading and release on
demand, a simpler, more economic loading system was needed in
which the P[n]s could directly interact with bioactive molecules.
Herein, we report a supramolecular approach to induce drug
transport based on a water-soluble pillar[5]arene. The molecular
recognition event facilitated a more soluble hydrophobic drug
molecule in aqueous solution. The reversible complexation and
decomplexation with drug molecules could be easily monitored
and controlled by pH variation.
As depicted in Scheme 1, two water-soluble pillar[5]arene
hosts 1 and 2 were chosen for this study. The synthesis of 1 and
2 was prepared by a ‘‘building-block approach’’ from two well-
known key intermediates that were available from inexpensive
starting materials.18 Norharmane (NHM) was selected as a
hydrophobic drug model to investigate the ability of the loading
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capacity and potential host–guest properties of 1 and 2. NHM,
known also as b-carboline, is a bioactive alkaloid, which widely
exists in animals and plants,19 and has been reported to exhibit
significant antioxidant abilities and neuroprotective effects against
neurotoxins20 and potent antitumor, antiviral, antimicrobial,
and antiparasitic activities in photodynamic therapy.21 In our
test approach, we observed a large excess of insoluble solid
NHM (2 mg) floating in the tested vial (1 mL H2O). However, the
excess insoluble NHM could be rapidly dissolved when the certain
amount of 1 (20 mg) was added to the system under gentle stirring
(1 min, 500 rpm), which suggests host 1 was able to facilitate the
solvation process of hydrophobic bioactive molecule. Under iden-
tical conditions, however, compound 2 did not lead to any apparent
solubilisation, which indicated that the terminal functional group
played a vital role for the selective recognition.
The 1H NMR was recorded to follow the solubilisation process.
As shown in Fig. 1, we found that the proton signals of NHM clearly
showed upfield shifts upon addition of 1. For example, the pyridine
ring proton (Ha) shifted from 8.82 ppm to 8.16 ppm, andHd on the
indole moiety moved from 8.25 ppm to 7.70 ppm, respectively. All
these signal changes were consistent with the shielding eﬀect
observed in other NHM-involved complexes.22 As expected,
the addition of 2 to the suspension of NHM did not cause
any significant variation in the 1H NMR spectra (Fig. S1, ESI†).
The detailed phase-solubility diagram (Fig. 1, plot of [NHM]
versus [1]) shows the solubility of the drug molecule was thus
increased by factor of 100 (up to 4.5 mgmL1) with the assistance
of pillararene host (Fig. S3, ESI†).
We gained more detailed recognition information between
host 1 and NHM through UV-vis and fluorescence examinations,
since NHM is also known for its excellent chemosensory response
and has been widely used as a molecular probe for biophysics
studies.23 In aqueous medium, the absorption spectrum of
saturated NHM solution showed two characteristic bands with
maxima at 348 nm and 372 nm that correspond to its neutral
and cationic forms, respectively (Fig. 2a). With gradual addition
of 1, the band belonging to the neutral form of NHM concomitantly
decreased, and the band belonging to the acid form increased,
which is due to the shifted ground state of NHM from prototropic
equilibrium towards its cationic form. In a fluorescent study, we
observed that the blue emission band at 450 nm, ascribed to the
cationic form of NHM, was rapidly quenched after addition of 1
(Fig. 2b). The Stern–Volmer quenching constant (Ksv), an indicator
of the degree of sensitivity of quencher, was found to be as high
as 1.36  105 M1 in our case (Fig. S4, ESI†), which is even
compatible to some reported efficient quenchers with high Ksv.
24
Scheme 1 Chemical structures of water-soluble pillar[5]arenes 1 and 2,
and bioactive model molecule norharmane (NHM).
Fig. 1 Partial 1H NMR spectra (400 MHz, D2O, 298 K) of (a) the saturated
aqueous solution of NHM, and suspensions of a fixed amount NHM (6.0mg)
after addition of (b) 1 mg, (c) 5 mg, (d) 20mg, (e) 60 mg 1, and (f) only 1. The
inserted figure is a phase-solubility diagram measured for NHM in the
presence of 1.
Fig. 2 Variation of the (a) absorption and (b) fluorescence (lex = 352 nm)
spectra of NHM as a function of the concentration of 1. From the bottom
to top of the arrows, the curves correspond to [1] = 0 to 1.36 mg mL1. The
inserted photos show the fluorescence quenching process (lex = 365 nm).
(c) The pH-triggered reversible complexation and discomplexation pro-
cesses between 1 and NHM. In all samples, the concentrations of NHM
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In fact, the fluorescence quenching process usually can be
caused by a collision process (dynamic quenching mechanism)
or by formation of a complex between quencher and fluorophore
(static quenching mechanism).
Here the obtained bimolecular quenching constant (kq) has
a value of B1012 M1 s1 (Fig. S4, ESI†), which is two orders
larger than the maximum value of diﬀusion-limited rate con-
stant (B1010 M1 s1) and indicates the observed quenching
mechanism is due to complex formation. Moreover, previous
studies focusing on natural b-carboline alkaloids found that the
chemical groups with lower oxidation potential facilitated the
fluorescence quenching since the protons transferred from
the singlet-excited b-carboline to the receptor.25 Considering
the relatively low oxidation potential of carboxylates, the rapid
quenching process induced by 1 could be attributed to the
electrostatic interaction between the cationic fluorophore
(singlet-excited NHM) and the negative COO group on 1. In
other words, the NHM favourably binds to the rim region where
there is a high concentration of carboxylate anion (as illustrated
in Scheme 1), instead of being embedded in the cavity of 1,
which is somewhat unique to many other hostguest complexes
based on pillararenes.26 However, it was still diﬃcult to deter-
mine the cavity’s hydrophobic eﬀect upon the complexation. The
Job plot showed the complex adapted the 1 : 1 NHM1 stoichio-
metry (Fig. S5, ESI†), which implied the binding of the first NHM
molecule resulted in a structural alternation that was unfavour-
able for binding the second guest. Using the Benesi-Hildebrand
equation, we determined that the binding constants Ka for NHM1
was 3.4  104 M1 (Fig. S6, ESI†).
Here the pH-triggered release was achieved because of the
pH-sensitivity of carboxylate group. Adding a little excess of
hydrochloric acid to a mixed solution of NHM and 1 immediately
resulted in a fast and obvious phase transition from a clear
solution to a turbid colloid (Fig. 2c), which was ascribed to the
precipitated carboxylic-acid form of pillar[5]arene 1.16c Since the
fluorescent intensity of NHM under acidic conditions (pH = 1.5)
is known to be approximately three times higher than in neutral
medium (pH = 7.0),27 we can estimate that over 90% of the
complexed drug molecules were released upon the reduction of
the pH value (Fig. S7, ESI†). The further addition of ammonia
changed the system to neutral medium, and the fluorescence of
NHM was regained correspondingly.
The cytotoxicity of 1 was exemplarily evaluated in diﬀerent
cell lines. Up to a concentration of 300 mMmL1, no cytotoxicity
could be observed in human kidney cells (HEK 293), human
liver cells (HepG2) and human monocyte cells (THP-1) in a MTS
assay (Fig. S8, ESI†). Furthermore, we tested in vitro cytotoxic
activity of the NHM1 system in A549 cells by MTT (3-(4,5-
dimethylthiazolyl)-2,5-diphenyltetrazolium bromide) for further
applications. We found that the toxicity for NHM obviously
decreased after supramolecular complexation (Fig. 3). For example,
cells treated with concentrations of 60 mg mL1 NHM (367 mM)
showed only aminor reduction in cell viability (B20%). In contrast,
the relative cell viability of the sample treated with NHM dissolved
in methanol sharply reduced (B95%). Previous studies showed
b-carboline alkaloids are characteristic for DNA binding.20b
Particularly at high dose condition, the intercalation between
b-carboline species into DNA may lead to conformational changes
and disrupt the normal mechanism of DNA replication, transcrip-
tion, and repair.21b Therefore, the observed toxicity reduction could
be ascribed to the lowered chance of NHM bound to the DNA in
nucleus and mitochondrion of cells. From the above results,
it could be demonstrated that this supramolecular induced drug
transport system diminished the toxicity of bioactive molecules
even at high concentrations of NHM.
In summary, we have presented a versatile, simplified hydro-
phobic guest transport system based on the pillararene. The
introduction of supramolecular interactions between P[5] deri-
vative and NHM exhibited improvement of the water solubility
of the bioactive molecule. Compared with individual NHM, the
supramolecular transport system containing both NHM and 1
showed a significant reduction of the drug’s cell toxicity, when at
higher concentration. Considering that the increased numbers of
P[n]s homologues (n = 6–14) contain larger cavities (in nanosize)
and more functional groups,28 we believe the pillararenes-based
guest transport system has great potential as drug delivery system.
This work was supported by Deutsche Forschungsgemeinschaft
(SFB 765) and Focus Area Nanoscale at Freie Universita¨t Berlin.
The authors thank Christina Ku¨hl for the assistance of cell viability
experiment. Dr Shengyi Dong acknowledges financial support
from the Alexander von Humboldt Foundation. The authors
acknowledge Dr P. Winchester for proof reading and Dr David
Mosser providing HeLa cells.
Notes and references
1 (a) Z. Laughrey and B. C. Gibb, Chem. Soc. Rev., 2011, 40, 363;
(b) K. I. Assaf and W. M. Nau, Chem. Soc. Rev., 2015, 44, 394.
2 (a) Z. Niu and H. W. Gibson, Chem. Rev., 2009, 109, 6024; (b) F. Lei,
M. A. Olson, D. Benitez, E. Tkatchouk, W. A. Goddard and J. F.
Stoddart, Chem. Soc. Rev., 2010, 39, 17; (c) J. Wu, A. Zawistowski,
M. Ehrmann, T. Yi and C. Schmuck, J. Am. Chem. Soc., 2011,
133, 9720; (d) F. Huang and O. A. Scherman, Chem. Soc. Rev.,
2012, 41, 5879; (e) S.-L. Li, T. Xiao, C. Lin and L. Wang, Chem. Soc.
Rev., 2012, 41, 5950; ( f ) Y. Ding, P. Wang, Y.-K. Tian and F. Wang,
Chem. Commun., 2013, 49, 5951; (g) S. Dong, B. Zheng, F. Wang and
F. Huang, Acc. Chem. Res., 2014, 47, 1982; (h) G. Ghale and W. M.
Nau, Acc. Chem. Res., 2014, 47, 2150; (i) Z. Qi and C. A. Schalley, Acc.
Chem. Res., 2014, 47, 2222; ( j ) G. Stephenson, R. M. Parker, Y. Lan,
Z. Yu, O. A. Scherman and C. Abell, Chem. Commun., 2014, 50,
7048; (k) J. A. Foster and J. W. Steed, Angew. Chem., Int. Ed., 2010,
49, 6718.





























































































This journal is©The Royal Society of Chemistry 2015 Chem. Commun., 2015, 51, 10326--10329 | 10329
3 (a) C. A. Lipinski, J. Pharmacol. Toxicol. Methods, 2000, 44, 235; (b) D. J.
Hauss, Adv. Drug Delivery Rev., 2007, 59, 667; (c) C. J. H. Porter,
N. L. Trevaskis and W. N. Charman, Nat. Rev. Drug Discovery, 2007,
6, 231.
4 (a) J. Li and X. J. Loh, Adv. Drug Delivery Rev., 2008, 60, 1000;
(b) Y. Chen and Y. Liu, Chem. Soc. Rev., 2010, 39, 495; (c) G. Chen
and M. Jiang, Chem. Soc. Rev., 2011, 40, 2254.
5 (a) R. Haag, Angew. Chem., Int. Ed., 2004, 43, 278; (b) T. Aida,
E. W. Meijer and S. I. Stupp, Science, 2012, 335, 813; (c) S. Biswas,
K. Kinbara, T. Niwa, H. Taguchi, N. Ishii, S. Watanabe, K. Miyata,
K. Kataoka and T. Aida, Nat. Chem., 2013, 5, 613.
6 (a) S. Nowag and R. Haag, Angew. Chem., Int. Ed., 2014, 53, 49;
(b) Y. Wang, S. Song, J. Liu, D. Liu and H. Zhang, Angew. Chem.,
Int. Ed., 2015, 54, 536.
7 (a) S. J. Loeb and J. A. Wisner, Angew. Chem., Int. Ed., 1998, 37, 2838;
(b) H. W. Gibson, N. Yamaguchi, L. Hamilton and J. W. Jones, J. Am.
Chem. Soc., 2002, 124, 4652; (c) F. Huang, F. R. Fronczek and
H. W. Gibson, J. Am. Chem. Soc., 2003, 125, 9272; (d) H. W. Gibson,
N. Yamaguchi and J. W. Jones, J. Am. Chem. Soc., 2003, 125, 3522;
(e) W. Jiang and C. A. Schalley, Proc. Natl. Acad. Sci. U. S. A., 2009,
106, 10425; ( f ) X. Yan, D. Xu, X. Chi, J. Chen, S. Dong, X. Ding, Y. Yu
and F. Huang, Adv. Mater., 2012, 24, 362; (g) L. Chen, Y.-K. Tian,
Y. Ding, Y.-J. Tian and F. Wang, Macromolecules, 2012, 45, 8412;
(h) Z. Qi, P. Malo de Molina, W. Jiang, Q. Wang, K. Nowosinski,
A. Schulz, M. Gradzielski and C. A. Schalley, Chem. Sci., 2012, 3, 2073;
(i) Z. Qi, C. Wu, P. Malo de Molina, H. Sun, A. Schulz, C. Griesinger,
M. Gradzielski, R. Haag, M. B. Ansorge-Schumacher and C. A.
Schalley, Chem. – Eur. J., 2013, 19, 10150; ( j) Z. Qi, N. L. Traulsen,
P. Malo de Molina, C. Schlaich, M. Gradzielski and C. A. Schalley, Org.
Biomol. Chem., 2014, 12, 503; (k) Y.-K. Tian, Z.-S. Yang, X.-Q. Lv,
R.-S. Yao and F. Wang, Chem. Commun., 2014, 50, 9477.
8 A. Harada, Acc. Chem. Res., 2001, 34, 456.
9 (a) J. S. Kim and D. T. Quang, Chem. Rev., 2007, 107, 3780;
(b) D.-S. Guo and Y. Liu, Chem. Soc. Rev., 2012, 41, 5907.
10 (a) K. Kim, Chem. Soc. Rev., 2002, 31, 96; (b) B. Vinciguerra, L. Cao,
J. R. Cannon, P. Y. Zavalij, C. Fenselau and L. Isaacs, J. Am. Chem.
Soc., 2012, 134, 13133; (c) D. Ma, G. Hettiarachchi, D. Nguyen,
B. Zhang, J. B. Wittenberg, P. Y. Zavalij, V. Briken and L. Isaacs,
Nat. Chem., 2012, 4, 503.
11 (a) T. Ogoshi, S. Kanai, S. Fujinami, T. Yamagishi and Y. Nakamoto,
J. Am. Chem. Soc., 2008, 130, 5022; (b) D. Cao, Y. Kou, J. Liang,
Z. Chen, L. Wang and H. Meier, Angew. Chem., Int. Ed., 2009,
48, 9721; (c) Z. Zhang, B. Xia, C. Han, Y. Yu and F. Huang, Org.
Lett., 2010, 12, 3285; (d) C. Li, Q. Xu, J. Li, F. Yao and X. Jia, Org.
Biomol. Chem., 2010, 8, 1568; (e) M. Holler, N. Allenbach, J. Sonet
and J.-F. Nierengarten, Chem. Commun., 2012, 48, 2576; ( f ) X. Shu,
S. Chen, J. Li, Z. Chen, L. Weng, X. Jia and C. Li, Chem. Commun.,
2012, 48, 2967–2969; (g) M. P. Sonawane, J. Jacobs, J. Thomas,
L. V. Meervelt and W. Dehaen, Chem. Commun., 2013, 49, 6310;
(h) T. Adiri, D. Marcianob and Y. Cohen, Chem. Commun., 2013,
49, 7082; (i) H. Zhang, X. Ma, J. Guo, K. T. Nguyen, Q. Zhang,
X.-J. Wang, H. Yan, L. Zhu and Y. Zhao, RSC Adv., 2013, 3, 368;
( j ) C. Li, J. Ma, L. Zhao, Y. Zhang, Y. Yu, X. Shu, J. Li and X. Jia,
Chem. Commun., 2013, 49, 1924; (k) L. Wu, Y. Fang, Y. Jia, Y. Yang,
J. Liao, N. Liu, X. Yang, W. Feng, J. Ming and L. Yuan, Dalton Trans.,
2014, 43, 3835; (l ) D.-D. Zheng, D.-Y. Fu, Y. Wu, Y.-L. Sun, L.-L. Tan,
T. Zhou, S.-Q. Ma, X. Zha and Y.-W. Yang, Chem. Commun., 2014,
50, 3201; (m) Y.-W. Yang, Y.-L. Sun and N. Song, Acc. Chem. Res.,
2014, 47, 1950; (n) H. Chen, J. Fan, X. Hu, J. Ma, S. Wang, J. Li, Y. Yu,
X. Jia and C. Li, Chem. Sci., 2015, 6, 197.
12 (a) Z. Zhang, G. Yu, C. Han, J. Liu, X. Ding, Y. Yu and F. Huang,
Org. Lett., 2011, 13, 4818; (b) X. Wang, K. Han, J. Li, X. Jia and C. Li,
Polym. Chem., 2013, 4, 3998; (c) K. Wang, C.-Y. Wang, Y. Zhang,
S. X.-A. Zhang, B. Yang and Y.-W. Yang, Chem. Commun., 2014,
50, 9458.
13 G. Yu, Z. Zhang, C. Han, M. Xue, Q. Zhou and F. Huang, Chem.
Commun., 2012, 48, 2958.
14 (a) Z. Zhang, Y. Luo, J. Chen, S. Dong, Y. Yu, Z. Ma and F. Huang,
Angew. Chem., Int. Ed., 2011, 50, 1397; (b) B. Xia, B. Zheng, C. Han,
S. Dong, M. Zhang, B. Hu, Y. Yu and F. Huang, Polym. Chem., 2013,
4, 2019; (c) X. Hu, X. Wu, S. Wang, D. Chen, W. Xia, C. Lin, Y. Pan
and L. Wang, Polym. Chem., 2013, 4, 4292; (d) X. Wang, H. Deng,
J. Li, K. Zheng, X. Jia and C. Li, Macromol. Rapid Commun., 2013,
34, 1856; (e) K. Wang, C.-Y. Wang, Y. Wang, H. Li, C.-Y. Bao, J.-Y. Liu,
S. X.-A. Zhang and Y.-W. Yang, Chem. Commun., 2013, 49, 10528;
( f ) C. Li, K. Han, J. Li, Y. Zhang, W. Chen, Y. Yu and X. Jia,
Chem. – Eur. J., 2013, 19, 11892; (g) Z.-Y. Li, Y. Zhang, C.-W.
Zhang, L.-J. Chen, C. Wang, H. Tan, Y. Yu, X. Li and H.-B. Yang,
J. Am. Chem. Soc., 2014, 136, 8577; (h) N. Song, D.-X. Chen, Y.-C. Qiu,
X.-Y. Yang, B. Xu, W. Tian and Y.-W. Yang, Chem. Commun., 2014,
50, 8231; (i) C. Li, Chem. Commun., 2014, 50, 12420; ( j) N. Song, D.-X.
Chen, M.-C. Xia, X.-L. Qiu, K. Ma, B. Xu, W. Tian and Y.-W. Yang,
Chem. Commun., 2015, 51, 5526.
15 W. Si, L. Chen, X.-B. Hu, G. Tang, Z. Chen, J.-L. Hou and Z.-T. Li,
Angew. Chem., Int. Ed., 2011, 50, 12564.
16 (a) Y.-L. Sun, Y.-W. Yang, D.-X. Chen, G. Wang, Y. Zhou, C.-Y. Wang
and J. F. Stoddart, Small, 2013, 9, 3224–3229; (b) H. Zhang, X. Ma,
K. T. Nguyen and Y. Zhao, ACS Nano, 2013, 7, 7853; (c) D.-D. Zheng,
D.-Y. Fu, Y. Wu, Y.-L. Sun, L.-L. Tan, T. Zhou, S.-Q. Ma, X. Zha and
Y.-W. Yang, Chem. Commun., 2014, 50, 3201; (d) P. Wang, Z. Li and
X. Ji, Chem. Commun., 2014, 50, 13114.
17 (a) G. Yu, W. Yu, Z. Mao, C. Gao and F. Huang, Small, 2015, 11, 919;
(b) Q. Duan, Y. Cao, Y. Li, X. Hu, T. Xiao, C. Lin, Y. Pan and L. Wang,
J. Am. Chem. Soc., 2013, 135, 10542; (c) Y. Cao, X.-Y. Hu, Y. Li, X. Zou,
S. Xiong, C. Lin, Y.-Z. Shen and L. Wang, J. Am. Chem. Soc., 2014,
136, 10762.
18 (a) T. Ogoshi, M. Hashizume, T.-A. Yamagishi and Y. Nakamoto,
Chem. Commun., 2010, 46, 3708; (b) Y. Ma, X. Ji, F. Xiang, X. Chi,
C. Han, J. He, Z. Abliz, W. Chen and F. Huang, Chem. Commun.,
2011, 47, 12340.
19 K. Touiki, P. Rat, R. Molimard, A. Chait and R. de Beaurepaire,
Psychopharmacology, 2005, 182, 562.
20 (a) H. Haghdoost-Yazdi, S.-S. Hosseini, A. Faraji, D. Nahid and
H. Jahanihashemi, Behav. Brain Res., 2010, 215, 136; (b) M. M.
Gonzalez, M. Pellon-Maison, M. A. Ales-Gandolfo, M. R. Gonzalez-
Baro, R. Erra-Balsells and F. M. Cabrerizo, Org. Biomol. Chem., 2010,
8, 2543.
21 (a) R. Cao, W. Peng, Z. Wang and A. Xu, Curr. Med. Chem., 2007,
14, 479; (b) C. de Meester, Mutat. Res., 1995, 339, 139.
22 A. Mallick, T. Katayama, Y. Ishibasi, M. Yasuda and H. Miyasaka,
Analyst, 2011, 136, 275.
23 A. Chakrabarty, A. Mallick, B. Haldar, P. Das and N. Chattopadhyay,
Biomacromolecules, 2007, 8, 920.
24 A. Mallick, M. C. Mandal, B. Haldar, A. Chakrabarty, P. Das and
N. Chattopadhyay, J. Am. Chem. Soc., 2006, 128, 3126.
25 Z. Miskolczy, M. Megyesi, L. Biczok and H. Gorner, Photochem.
Photobiol. Sci., 2011, 10, 592.
26 (a) P. Wang, Y. Yao and M. Xue, Chem. Commun., 2014, 50, 5064;
(b) X. Chi, M. Xue, Y. Ma, X. Yan and F. Huang, Chem. Commun.,
2013, 49, 8175; (c) W. Chen, Y. Zhang, J. Li, X. Lou, Y. Yu, X. Jia and
C. Li, Chem. Commun., 2013, 49, 7956; (d) J. Fan, H. Deng, J. Li, X. Jia
and C. Li, Chem. Commun., 2013, 49, 6343.
27 F. Tomas Vert, I. Zabala Sanchez and A. Olba Torrent, J. Photochem.,
1983, 23, 355.
28 T. Ogoshi, N. Ueshima, F. Sakakibara, T.-A. Yamagishi and T. Haino,
Org. Lett., 2014, 16, 2896.
Communication ChemComm
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
2 
M
ay
 2
01
5.
 D
ow
nl
oa
de
d 
on
 0
9/
12
/2
01
5 
14
:4
2:
20
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
